US Stock Market Move | HUTCHMED (HCM.US) rose nearly 4% after positive results from the SAFFRON III study.
On Monday, Hutchison China MediTech (HCM.US) rose nearly 4%, reaching $12.67.
On Monday, HUTCHMED (HCM.US) rose nearly 4%, closing at $12.67. In terms of news, on August 17, HUTCHMED announced that the SAFFRON Phase III study of the combination therapy of gorasiv (savatinib) and osimertinib (Tagrisso) achieved positive top-line results. The study targeted EGFR-mutant non-small cell lung cancer patients who had previously progressed on osimertinib treatment and had tumors with high levels of MET overexpression or amplification. The results showed that the combination therapy had statistically and clinically significant improvements in progression-free survival (PFS) and overall survival (OS) compared to platinum-based doublet chemotherapy.
Related Articles
HK Stock Market Move | NEW VISION CO (02632) surged over 27% in early trading, marking its first partnership with a leading German automotive manufacturer for model specific allocation. The companys production reserves continue to expand.
Bank of America: Nvidia and Broadcom have the widest holdings, while Micron and AMD saw significant increases from active funds.
HK Stock Market Move | ASCLETIS-B (01672) rose nearly 5% in early trading as the company launched a Phase I obesity study in the U.S. for ASC36 oral tablets.
HK Stock Market Move | NEW VISION CO (02632) surged over 27% in early trading, marking its first partnership with a leading German automotive manufacturer for model specific allocation. The companys production reserves continue to expand.
Bank of America: Nvidia and Broadcom have the widest holdings, while Micron and AMD saw significant increases from active funds.
HK Stock Market Move | ASCLETIS-B (01672) rose nearly 5% in early trading as the company launched a Phase I obesity study in the U.S. for ASC36 oral tablets.
RECOMMEND
